SLC6A14 impacts cystic fibrosis lung disease severity via mTOR and epithelial repair modulation

Julia Mercier

Institut national de la santé et de la recherche médicale: INSERM

Claire Calmel

Institut national de la santé et de la recherche médicale: INSERM

Julie Mézinèle

Institut national de la santé et de la recherche médicale: INSERM

Erika Sutanto

Telethon Kids Institute

Fatiha Merabtene

Institut national de la santé et de la recherche médicale: INSERM

Elisabeth Longchamp

Hôpital Foch: Hopital Foch

Edouard Sage

Hôpital Foch: Hopital Foch

Anthony Kicic

Telethon Kids Institute

Pierre-Yves Boëlle

iPLESP: Institut Pierre Louis d'Epidemiologie et de Sante Publique

Harriet Corvol

Institut national de la santé et de la recherche médicale: INSERM

Manon Ruffin

Institut national de la santé et de la recherche médicale: INSERM

Loic Guillot (✉ loic.guillot@inserm.fr)

Institut national de la santé et de la recherche médicale: INSERM <https://orcid.org/0000-0001-6853-7945>

Research Article

Keywords: cystic fibrosis, lung function, modifier genes, SLC6A14, amino acid transporter, bronchial epithelial cells

Posted Date: August 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-591564/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Cystic fibrosis (CF), due to variants in *CFTR* gene, is associated with chronic infection/inflammation responsible for airway epithelium alteration and lung function decline. Modifier genes induce phenotype variability between people with CF (pwCF) carrying the same *CFTR* variants. Among these, the gene encoding for the amino acid transporter SLC6A14 has been associated with lung disease severity and age of primary airway infection by the bacteria *Pseudomonas aeruginosa*. In this study, we investigated whether the single nucleotide polymorphism (SNP) rs3788766, located within *SLC6A14* promoter, is associated with lung disease severity in a large French cohort of pwCF. We also studied the consequences of this SNP on *SLC6A14* promoter activity using a luciferase reporter and the role of SLC6A14 in mammalian target of rapamycin (mTOR) signaling pathway and airway epithelial repair. We confirm that *SLC6A14* SNP rs3788766 is associated with lung disease severity in pwCF (p=0.020; n=3,257, pancreatic insufficient, aged 6 to 40 years old), with the minor allele G being deleterious. In bronchial epithelial cell lines deficient for *CFTR*, *SLC6A14* promoter activity is reduced in the presence of the rs3788766 G allele. SLC6A14 inhibition with a specific pharmacological blocker reduced ³H-arginine transport, mTOR phosphorylation and bronchial epithelial repair rates in wound healing assays. To conclude, our study highlights that *SLC6A14* genotype might affect lung disease severity of people with cystic fibrosis via mTOR and epithelial repair mechanisms modulation in the lung.

Introduction

Cystic fibrosis (CF), the most common lethal autosomal recessive genetic disease in the Caucasian population, results from pathogenic variants in the CF transmembrane conductance regulator (*CFTR*) gene [1-3]. Manifestations of CF occur in several organs including the pancreas, liver and the intestine [4-6], but lung disease is the main cause of morbidity and mortality in people with CF (pwCF). CF lung disease is characterized by chronic airway colonization with microorganisms, including the most common CF life-threatening pathogen *Pseudomonas aeruginosa*, exacerbated inflammation and lung tissue damage due to abnormal repair of the airway epithelium [7].

Variability in the clinical phenotype of pwCF carrying identical *CFTR* variants and living in the same environment involves genetic modifiers, which are expected to contribute to almost 50% of CF lung phenotype [8]. In a large cohort of pwCF (n=6,365), we previously identified five CF lung disease modifier loci by genome wide association studies (GWAS) [9], including the solute carrier family 6 member 14 gene (*SLC6A14*, also known as *ATB^{0,+}*). *SLC6A14* is located on chromosome X and encodes for the neutral and cationic amino acid transporter SLC6A14 that concentrates amino acids into cells (with the exception of proline, glutamate and aspartate) by using a sodium and chloride electrochemical gradient [10-12]. This transporter has been shown to be upregulated in several cancers [13] and to be involved in cell growth, proliferation and the mechanistic target of rapamycin (mTOR) pathway [14].

The *SLC6A14* gene has pleiotropic effects in pwCF [13], with several *SLC6A14* single nucleotide polymorphisms (SNPs) being associated with different phenotypes such as meconium ileus (MI)

occurrence, a severe neonatal intestinal obstruction [15], lung disease severity [9,16,17], and age at first *P. aeruginosa* infection [16,17]. In particular, the SNP rs3788766, located within the promoter region of *SLC6A14*, has been previously associated with both MI and lung function variability in pwCF [17,18,16]. However, the functional consequences of this SNP on *SLC6A14* expression and function are still unknown.

Here, we first analyzed the association between *SLC6A14* SNP rs3788766 and lung function by genotyping a large French cohort of pwCF. Then, we studied how rs3788766 regulate transcriptional activity of the *SLC6A14* promoter. Finally, we investigated the possible consequences of *SLC6A14* activity modulation in CF bronchial epithelial cells.

Materials And Methods

Genotype-phenotype association study

Participants

As of January 31st, 2021, 4,975 pwCF had been included in the French CF modifier gene study [9]. The study was approved by the French Human Ethics Committee (CPP n°2004/15), and information collected by the *Commission Nationale de L'informatique et des Libertés* (n°04.404). Informed written consent was obtained from each participant and/or parents or guardians. For the analysis, we excluded pancreatic-sufficient participants since they had milder disease (n = 820), non-genotyped participants for the *SLC6A14* SNP rs3788766 (n = 436), and participants without forced expiratory volume in 1 s (FEV₁) measurements (n = 177). We also excluded participants under 6 years of age, since their spirometry data was less reliable, as well as those over 40 years old, in order to limit selective survival bias (n = 285).

Lung function and genotyping

Measurements of FEV₁ were quarterly collected according to international CF care recommendations [19] and expressed as percent-predicted values (ppFEV₁) using Global Lung Function Initiative (GLI) equations [20]. To assess the lung disease severity, FEV₁ were transformed to the Survival Adjusted Kulich Normalized (SaKnorm Z-value) CF-specific lung phenotype [21]. Lung function and lung disease severity were analyzed over the last 3 years; except for post-lung transplant patients and patients under CFTR modulator therapy (ivacaftor and lumacaftor-ivacaftor) for whom FEV₁ measurements were analyzed over the 3 years prior to the event. *SLC6A14* SNP rs3788766 was genotyped using Kompetitive Allele Specific PCR (KASP) chemistry (LGC, Teddington, UK).

Immunohistochemistry

Human lung biopsies were obtained from a healthy 51-year-old male smoker and from a 29 years old male with CF (homozygous for the F508del variant), respectively from Hôpital Foch, Suresnes 92150, France. Biopsies were collected and processed in compliance with the current French public health legislation (articles L.1235-2 and L.1245-2, code de la santé publique, www.legifrance.gouv.fr). The institution informed the participant and made sure that they were not opposed to the use of surgical samples for research purposes. Staining was performed using 5- μ m thick paraffin sections from formalin-fixed paraffin-embedded lung biopsies. Immunolabeling for SLC6A14 was performed on a Bond-III® automat (Leica, Leica Biosystems, Nussloch, Germany) using anti-SLC6A14 antibody (PA5-51855, Invitrogen, Carlsbad, CA, USA; 1:100).

Reagents

SLC6A14 inhibitor α -methyltryptophan (α -MT; M8377 was from Sigma-Aldrich, Saint-Quentin Fallavier, France) was solubilized in 100% methanol (MeOH) to achieve 1, 2.5 or 5 mM (used concentrations are specified in figures legends). Equivalent volumes of MeOH alone were used for control conditions, thus reaching 0.87%, 2.18% and 4.36% respectively.

Cell cultures

Human bronchial epithelial cell lines Calu-3-*CFTR*-WT and Calu-3 *CFTR*-KD, kindly provided by Dr. Marc Chanson [22] (University of Geneva, Geneva, CH), were cultured in 75 cm² flasks (TPP, Techno Plastic Products, Trasadingen, Switzerland) in MEM-Glutamax (Invitrogen) medium supplemented with SVF 10% (Eurobio, Courtaboeuf, France), penicillin-streptomycin (100 U/mL, Invitrogen), sodium pyruvate 5% (Invitrogen), essential amino acids 1 mM (Invitrogen), and HEPES buffer 10 mM (Thermo Scientific, Waltham, Massachusetts, USA). Calu-3 cells were then seeded in 12 (3-3.5x10⁵ cells/well) or 24 wells (2x10⁵ cells/well) wells-plates (TPP) and maintained at 37°C in a humidified atmosphere with 5% CO₂. Non-CF and CF primary human bronchial epithelial cells (HBEC) (Epithelix, Plan-les-Ouates, Switzerland) (characteristics in **Table 3**) were grown on plastic supports (1x10⁵ cells/well) until confluent in hAEC culture medium supplemented with antibiotics (Epithelix).

SLC6A14 promoter activity

Gaussia luciferase (GLuc) reporters driven by the *SLC6A14* promoter harboring either the A or G allele of rs3788766 (GeneCopoeia, Rockville, MD, USA) were used. Calu-3-*CFTR*-KD cells were seeded in 24-well plates and transfected at 60% confluence with 1 μ g/ml of the GLuc *SLC6A14* promoter reporter using Lipofectamine 3000 (Invitrogen). After 24 h of transfection, culture media were collected, centrifuged 10

min at 10,000x *g* and supernatants were stored at -20°C. *SLC6A14* promoter activity was quantified by measuring Gaussia luciferase and secreted embryonic alkaline phosphatase (SEAP) used as endogenous reporter, was measured using Secrete-Pair™ Dual Luminescence Assay kit (GeneCopoeia). *SLC6A14* promoter activity is represented as the ratio of GLuc normalized by SEAP.

L-Arginine uptake quantification

SLC6A14 amino acid transport was studied as described by others [23]. Briefly, cells cultured in 12-well plates were washed and then incubated in HEPES buffer (25 mM HEPES, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 0.8 mM MgSO₄, 5 mM Glucose, pH = 7.4) for 30 min at 37°C. Cells were then incubated with 300 µl of HEPES buffer supplemented with 100 µM Arginine and Arginine Monohydrochloride L-[2,3,4-³H] (L-Arginine-2,3,4-³H, 1 µCi/mL, specific activity: 54.5 Ci/mmol, lot: 2422780, PerkinElmer, Villebon-sur-Yvette, France) for 15 min and washed 3 times on ice with ice-cold HEPES with 10 mM Arginine (inhibition of uptake). Finally, cells were lysed with 400 µl 0.5M NaOH for 15 min while shaking on ice. Radioactivity levels were measured in 300 µl of sample in 7 mL of a scintillation liquid Ecolite Plus (MP Biomedicals, Illkirch-Graffenstaden, France) and using Hidex 300SL (LabLogic ScienceTec, Villebon-sur-Yvette, France) equipment.

Wound-healing assay

Cell monolayers grown on plastic supports were injured mechanically (3 wounds per well) as previously described [24,25]. Afterwards, cells were washed with their culture medium to remove detached cells and treated with either α-MT (1, 2.5 or 5 mM) or MeOH which acted as vehicle control (respective equivalent volumes of MeOH alone). Photographs of the wounds were taken at two different positions on each wound using an inverted microscope with a X4 objective at t=0 h and t=6 h post-wounding. Images were analyzed with Image J software (<https://imagej.nih.gov/ij/index.html>) to measure areas of the wounds at t=0 h and t=6 h and mean wound closure (% of the area at t=0 h) were calculated.

Cytotoxicity measurement

Toxicity of α-MT was verified using a commercially available assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay, Promega, Madison, WI, USA).

Protein extraction and Western blot

Protein extracts (20 µg) in RIPA buffer supplemented with antiprotease-antiphosphatase (Halt™ Protease and Phosphatase Inhibitor Single-Use Cocktail, Thermo Scientific) were reduced and size-separated on 4-15% Mini-PROTEAN® TGX Stain-Free™ Precast Gels (Bio-Rad, Hercules, CA, USA) and transferred onto nitrocellulose membranes using an iBlot2™ Gel Transfer Device and iBlot2™ Nitrocellulose Regular Stacks (IB23001, Invitrogen). Membranes were incubated with specific primary antibodies followed by corresponding secondary-HRP antibodies. Mouse anti-β-actin antibody (A2228) (1/1000) was from Sigma-Aldrich. Rabbit anti-phospho-mTOR (#2971, 1/1000), rabbit anti-mTOR (#2983, 1/1000), anti-mouse HRP (#7076, 1/10000) and anti-rabbit (#7074, (1/5000) antibodies were from Cell Signaling Technology (Denver, CO, USA). Immunodetection was revealed using Clarity™ Western ECL Substrate (#170-5061, Bio-Rad). Image acquisition was performed using Las-3000 (Fujifilm, Bussy-Saint-Georges, France). Densitometric quantification was performed using Image J software.

Statistical analysis

Genotype-phenotype analysis

Descriptive statistics are reported as mean ± standard deviation (SD) or percentages. Association between lung disease severity and *SLC6A14* rs3788766 genotypes was evaluated by linear regression. We applied additive SNP coding, and the reference allele (i.e., the allele with the highest frequency in the European population) was taken from annotations of the human genome (<http://www.ensembl.org>). Fisher's exact test was used to test conformance of the allele frequencies with the Hardy-Weinberg equilibrium. A *P*-value of less than 5% was interpreted as evidence of a statistically significant association. Analyses were carried out using R software (version 3.6.3, <http://www.R-project.org/>).

In vitro data

All data are presented as mean ± SEM and the number of repeated experiments is indicated in the figure legends. GraphPad Prism version 7.05 (GraphPad Software, San Diego, CA, USA) was used to analyze all data. Paired or unpaired t-tests were used to compare two groups. One-way ANOVA were used for comparison of more than two groups and followed by appropriate post-hoc tests as indicated in the figure's legends. Values of *p*<0.05 were considered to be significant. In figures, statistical differences are indicated as *p*<0.05 (*), *p*<0.01 (**) and *p*<0.001 (***) or non-significant (NS).

Results

***SLC6A14* SNP rs3788766 is associated with lung function in people with CF**

Among the 4,975 pwCF included in the French CF modifier gene study (i.e. 70% of French pwCF) and after application of the exclusion criteria, 3,257 pwCF were analyzed in the genotype/phenotype association study. Demographic characteristics of the participants are summarized in **Table 1**. The minor allele frequency (MAF) of *SLC6A14* SNP rs3788766 in our cohort was 0.38, similar to that reported in

Europeans (0.36). As *SLC6A14* is located on the X chromosome, Hardy-Weinberg equilibrium *p*-value was computed by Fisher's exact test among females. Results showed that our cohort does not significantly diverge from Hardy-Weinberg equilibrium (*p*-value=0.459). We also found that *SLC6A14* SNP rs3788766 was associated with lung function with the G allele being deleterious. Linear regression models estimated that pwCF carriers of the minor allele G had a significant increase in lung disease severity, which was measured by an average loss in SaKnorm Z-value of 0.038 ± 0.016 for each G allele (*p*=0.020) (**Table 2**). Overall, an average decrease of ~1.5% of ppFEV₁ was observed in patients carrying at least one rs3788766 G allele (**Table 2**).

***SLC6A14* rs3788766 genotype affects *SLC6A14* promoter activity**

The *SLC6A14* SNP rs3788766, located within *SLC6A14* promoter (**Fig. 1A**), is likely to affect *SLC6A14* mRNA expression. Quantitative-trait Loci (QTL) expression data extracted from GTEx (<https://www.gtexportal.org/home/>) show that rs3788766 G is associated with a decrease of *SLC6A14* transcript expression in different tissues (**Fig. 1B**), including the pituitary (*p*-value = 3.0×10^{-8}) and the minor salivary gland (*p*-value = 1.8×10^{-5}). In the lung, a diminished but not statistically significant expression is observed (AA vs GG genotypes). It is worth mentioning that, for the GTEx project, the preferred location for the lung tissue collection is in the inferior segment of the left upper lobe, 1 cm below the pleural surface, avoiding any large arteries, veins, and bronchi. We observed by immunohistochemistry that *SLC6A14* is predominantly expressed in the bronchial epithelium of pwCF (**Fig. 1C**). Therefore, *SLC6A14* expression using QTL analysis might not inform about SNP consequences on *SLC6A14* expression in the lung. Thus, to determine whether rs3788766 affects *SLC6A14* promoter activity in bronchial epithelial cells, we used *SLC6A14* promoter reporters carrying either the A or the G allele of this SNP and assessed the reporters expression. We observed that Calu-3-*CFTR*-KD cells transfected with *SLC6A14* promoter reporter plasmid carrying the G allele had a lower luciferase activity (12.1% reduction) compared to cells transfected with the A allele (**Fig. 1D**). This result indicates that the G allele of rs3788766, i.e. the minor allele, is associated with a decreased *SLC6A14* promoter activity.

***SLC6A14* inhibition in human bronchial epithelial cells regulate mTOR phosphorylation and epithelial repair**

Since the *SLC6A14* rs3788766 G allele is likely to reduce *SLC6A14* mRNA expression level and consequently its activity as an amino acid transporter, we sought to investigate the cellular consequences of a decreased activity of *SLC6A14* in CF bronchial epithelial cells. Thus, we inhibited its activity in bronchial epithelial cells using α-MT, a specific pharmacological blocker of *SLC6A14* [26]. Firstly, we showed that α-MT induced a 54%-decrease of ³H-Arginine transport in Calu-3-*CFTR*-KD cells (**Fig. 2A**). A similar effect was observed in Calu-3-*CFTR*-WT (**Fig. S2A**). We then measured LDH release to ensure that α-MT was not toxic at the doses used (**Fig. S1**). We showed that cytotoxicity levels in Calu-3-*CFTR*-

KD treated with 1mM, 2.5mM and 5mM of α -MT were similar to those of cells treated with vehicle (**Fig. S1A**). As SLC6A14 is involved in colon cancer cell proliferation, migration and invasion [27], we wondered whether it could play a role in bronchial epithelial repair, a process which involves both cell proliferation and migration mechanisms. Thus, we performed scratch assay experiments on Calu-3-*CFTR*-KD monolayers, treated or without α MT at t=0 h and for the following 6 h of repair (**Fig. 2B and C**). Quantitative analysis highlighted a dose-dependent inhibition of wound closure with decreases of 8%, 27% and 39%, at 1mM, 2.5mM and 5mM of α -MT, respectively (**Fig. 2B**). In contrast, no significant wound closure inhibition was observed at 1mM and 2.5mM of α -MT in Calu-3-*CFTR*-WT, but a 31% decrease of wound closure was observed at 5mM of α -MT (**Fig. S2B**). To determine that this effect was not restricted to the Calu-3 cell lines, we performed similar experiments in primary HBECs isolated from patient with CF homozygous for the F508del *CFTR* variant (**Fig. 3**) or from healthy subjects (**Fig. S3**). Significant decreases of 25% and 36% of arginine transport were observed in CF HBECs treated with 2.5mM and 5mM of α -MT, respectively (**Fig. 3A**). Similar to the Calu-3 cells, no increase in cytotoxicity has been observed in non-CF HBECs treated or not with α -MT (**Fig. S1B**). A decrease of 32% and 56% of wound closure after 6 h of repair was observed in CF HBECs with 2.5mM and 5mM of α -MT (**Fig. 3B**), respectively, while 26% and 79% decreases were found in non-CF HBECs with 2.5mM and 5mM of α -MT (**Fig. S3A**), respectively. Finally, we wondered if SLC6A14 amino acid transport inhibition could have an impact on mTOR activity in primary bronchial epithelial cells, as it was previously shown in pancreatic and colonic cells [14,27]. Therefore, we evaluated mTOR activation by western blot in primary HBECs treated or not with 2.5mM of α -MT. From results generated, we observed that SLC6A14 activity inhibition induces a significant decrease of mTOR phosphorylation in primary CF (**Fig. 3C**) cells. A similar effect is observed in non-CF (**Fig. S3B**) HBECs, however without reaching significance.

Discussion

Lung disease severity is highly variable among pwCF, with *CFTR*, the environment and modifier genes all contributing to this variability. Among the modifier genes, *SLC6A14* is of particular interest because it has been associated with both lung and digestive phenotypes in pwCF [9,16-18]. This suggests a major pleiotropic role of SLC6A14 in the overall pathophysiology of the disease [13]. Here, we confirmed the association between *SLC6A14* SNP rs3788766 and the lung function of pwCF, and further demonstrated that carrying the minor allele of rs3788766 induces a decreased *SLC6A14* promoter activity. We finally demonstrated that a reduced SLC6A14 amino acid transport activity alters wound repair mechanisms and modulates the mTOR pathway in human CF bronchial epithelial cells.

Our study first showed, using a large French CF cohort (n=3,257), that pwCF carrying at least one minor allele G of the *SLC6A14* SNP rs3788766 exhibit reduced lung function compared to those carrying two major allele A, confirming prior studies [16,17]. Li *et al.* performed a sub-analysis from the original 1,661 Canadian CF Gene Modifier Study participants of a previous study [18] and showed that rs3788766 is associated with both pediatric lung disease severity and earlier age at first acquisition of *P. aeruginosa* [16]. Other *SLC6A14* SNPs, also associated with lung function of pwCF, have been identified either by GWAS [9] or genotyping [13]. Beside lung phenotype, Sun *et al.* showed that the SNP rs3788766

is associated with digestive manifestations of CF, such as increased MI susceptibility in a cohort of 3,763 pwCF [15]. Those results were further confirmed in a genome-wide association investigation performed by the International CF Gene Modifier Consortium with 6,770 pwCF [28]. Altogether, these results emphasize the major involvement of this particular SNP of *SLC6A14* in CF clinical variability.

To understand how this SNP can contribute to CF pathophysiology and because of its location within *SLC6A14* regulatory region, we evaluated its impact on *SLC6A14* promoter activity. We found that the minor allele G, previously identified as the deleterious allele regarding CF patient's lung function, is associated with a decrease of *SLC6A14* promoter activity in bronchial epithelial cells. This is in contradiction with eQTL data in GTEX lung samples. However, as evoked above, this discrepancy likely results from GTEX lung samples collection avoiding bronchi. In addition, *SLC6A14* eQTLs were already shown not to colocalize with lung GWAS associated evidence [28]. This is the first report showing that a *SLC6A14* SNP might influence *SLC6A14* transcription in the context of CF. Indeed, *SLC6A14* expression and function have been mostly investigated in cancers so far [29]. It is worth mentioning that, using a similar method, a recent report has shown that the obesity-associated *SLC6A14* SNP rs2011162 also reduced *SLC6A14* expression [30].

Recently, some studies have explored the role of *SLC6A14* in CF pathophysiology and began to explain the reasons for its identification as a modifier gene of CF lung and intestinal diseases. Di Paola *et al.* showed that the inhibition of *SLC6A14* amino acid transport increased *P. aeruginosa* attachment to human bronchial epithelial cells by enhancing L-arginine levels in the airway surface liquid [23]. Arginine transport through *SLC6A14* also seems to increase F508del-CFTR protein by enhancing nitric oxide (NO) production and activating cGMP or PKG pathways [31]. NO production increase has also been suggested to contribute to anti-infectious response because it is well-known to have bactericidal effects on *P. aeruginosa* [32]. Thus, *SLC6A14* seems to modulate CFTR activity and could participate in the infectious process of CF airways by *P. aeruginosa*. Concerning the role of *SLC6A14* in the intestine, it has been suggested that *SLC6A14* involvement in MI susceptibility could be related to intestinal fluid secretion defect in CF, which was worsened in *Slc6a14*-KO CF mice carrying the major mutation F508del [33].

Here, we report, for the first time, that *SLC6A14* is involved in bronchial epithelial repair. In healthy epithelia, repair processes involving cell proliferation, migration and differentiation, facilitate epithelial integrity restoration and function. In CF, repair mechanisms are altered and chronic infections with various pathogens and exacerbated inflammation induce progressive epithelial damage [34]. Our results demonstrated that, in Calu-3 cells and primary HBEC, pharmacological inhibition of *SLC6A14* activity resulted in a delayed epithelial repair. *SLC6A14* involvement in cell migration and proliferation has been previously described. Indeed, Sikder *et al.* first showed that *SLC6A14* function favors cell proliferation and invasion in colon cancer LS174T cell line [27]. In addition, Mao *et al.* showed that *SLC6A14* overexpression or knockdown respectively promotes or inhibits migration and proliferation of colorectal cancer cells (HCT-116 and Caco-2 cells) *in vitro* [35]. They also found that the pharmacological inhibitor α -MT inhibited cell proliferation as well as the fact that *SLC6A14* promoted colorectal cancer cell

proliferation and migration via the JAK2/STAT3 pathway. SLC6A14 involvement in cell proliferation has also been shown in other cancer cells such as pancreatic cancer cells [14].

In addition to its role in epithelial repair, we highlighted that it may be involved in the mTOR pathway. The mTOR pathway balances anabolism and catabolism in order to control key cellular processes such as cell growth or proliferation. It is very sensitive to amino acids starvation especially leucine and arginine [36]. SLC6A14 implication in mTOR pathway was previously described in pancreatic cancer cell lines [14] for which α -MT-mediated SLC6A14 blockade induces the decreased phosphorylation of proteins involved in mTOR pathway including 4E-BP1, eIF-2 α and S6kinase. This interplay between SLC6A14 and mTOR was also recently confirmed in colon cancer LS174T cell line treated with α -MT [27]. In intestinal epithelium, mTOR is involved in wound healing and the re-establishment of barrier function following injury [37]. Consistent with the literature, we confirmed the relation between SLC6A14 activity and mTOR activation. However, how airway epithelial repair, mTOR and SLC6A14 are related remains unknown. Recently, SLC6A14 was shown to be a target for Wnt-signaling [27], which is known to be one of the key pathways involved in lung repair and regeneration in response to injury [38]. Further work is thus necessary to fully understand the consequences of SLC6A14 blockade on the molecules of the mTOR pathway specifically related to this wound repair process.

To conclude, we confirmed that *SLC6A14* rs3788766 genotype influences the lung disease severity of pwCF. This study also showed that *SLC6A14* might influence CF lung phenotype *via* mTOR signaling pathway and epithelial repair processes modulation.

Declarations

Acknowledgements

We would like to thank the patients, care providers and clinic coordinators at CF Centres, as well as the Principal Investigators in the several contributing French CF Centres:

M. ABELY, American Memorial Hospital, Reims / C. BAILLY PICCINI, CHU de Nice, Nice / C. BELLEGUIC, Hôpital Pontchaillou, Rennes / K. BESSACI, American Memorial Hospital, Reims / T. BIHOUEE, Hôpital Mère-Enfant, Nantes / Y. BILLON, Hôpital de Brabois, Vandoeuvre les Nancy / F. BRÉMONT, Hôpital des Enfants de Toulouse, Toulouse / J. BROUARD, Centre Hospitalier Universitaire de Caen, Caen / S. BUI, Hôpital Des Enfants Groupe Pellegrin, Bordeaux / P.R. BURGEL, Hôpital Cochin, Paris / B. CAMARA, Hôpital de la Tronche, Grenoble / M.C. HERAUD, Centre Hospitalier Estaing, Clermont-Ferrand / R. CHIRON, Hôpital Arnaud de Villeneuve, Montpellier / E. COIRIER-DUET, Hôpital André Mignot, Le Chesnay / L. COSSON, Hôpital Clocheville, Tours / M.L. DALPHIN, Centre Hospitalier Universitaire de Besançon, Besançon / I. DANNER BOUCHER, Centre Hospitalier Universitaire de Nantes, Nantes / V. DAVID, Hôpital Mère-Enfant, Nantes / E. DENEUVILLE, Hôpital Sud Annexe Pédiatrique, Rennes / P. DOMBLIDES, Hôpital Haut Lévêque, Pessac / S. DOMINIQUE, Centre Hospitalier Universitaire Charles Nicolle, Rouen / J.C. DUBUS, Hôpital d'Enfants de la Timone, Marseille / N. DUFEU, Hôpital Nord, Marseille / I. DURIEU, UCBL1, Groupe Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite / S. DURY, Hôpital Maison Blanche,

Reims / R. EPAUD, Centre Hospitalier Intercommunal de Créteil, Créteil / FANTON,A., Hôpital d'Enfants du Bocage, Dijon / M. FAYON, Hôpital Des Enfants Groupe Pellegrin, Bordeaux / P.FOUCAUD, Hôpital André Mignot, Le Chesnay / M. GERARDIN, Hôpital Robert Debré, Paris / J.L. GINIES, Centre Hospitalier Universitaire d'Angers, Angers / D. GRENET, Hôpital Foch, Suresnes / D. HUBERT, Hôpital Cochin, Paris / F. HUET, Hôpital d'Enfants du Bocage, Dijon / R. KESSLER, Hôpital Civil, Strasbourg / J. LANGUEPIN, Centre Hospitalier, Limoges / M. LAURENS, Centre Hospitalier Universitaire de Caen, Caen / M. LE BOURGEOIS, Necker Hôpital d'Enfants Malades, Paris / P. LE ROUX, Hôpital Jacques Monod, Montivilliers / S. LEROY , CHU de Nice, Nice / C. LLERENA, Hôpital de la Tronche, Grenoble / J. MACEY, Centre Hospitalier Universitaire de Bordeaux, Bordeaux / J. MANKIKIAN, Hôpital Clocheville, Tours / C. MARGUET, Centre Hospitalier Universitaire Charles Nicolle, Rouen / L. MELY, Hôpital Renée Sabran, Giens / M. MITTAINE, Hôpital des Enfants de Toulouse, Toulouse / A. MUNCK, Hôpital Robert Debré, Paris / M. MURRIS-ESPIN, Hôpital Larrey, Toulouse / R. NOVE JOSSERAND, Groupe Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite / C. PERISSON, Groupe Hospitalier Sud Réunion, Saint-Pierre de la Réunion / I. PIN, Hôpital de la Tronche, Grenoble / A. PREVOTAT, Hôpital Calmette, Lille / S. RAMEL, Centre de Perharidy, Roscoff / C. RAMES, Hôpital Nord, Amiens / G. RAULT, Centre de Perharidy, Roscoff / P. REIX, Hôpital Femme Mère Enfant, Bron / N. REMUS, Centre Hospitalier Intercommunal de Créteil, Créteil / M. REYNAUD-GAUBERT, Hôpital Nord, Marseille / B. RICHAUD-THIRIEZ, Centre Hospitalier Universitaire de Besançon, Besançon / J.L. RITTIE, Hôpital d'Enfants, Saint-Denis de la Réunion / M. SCALBERT-DUJARDIN, Centre Hospitalier de Dunkerque, Dunkerque / I. SERMET-GAUDELUS, Necker Hôpital d'Enfants Malades, Paris / N. STREMLER, Hôpital d'Enfants de la Timone, Marseille / V. STORNI, Centre Hospitalier Bretagne Atlantique, Vannes / A. TATOPOULOS, Hôpital d'Enfants, Vandoeuvre les Nancy / F. TROUSSIER, Centre Hospitalier Universitaire d'Angers, Angers / P. VIGNERON, Centre Hospitalier Bretagne Sud, Lorient / L. WEISS, Hôpital de Haute-pierre, Strasbourg / N. WIZLA, Hôpital Jeanne de Flandre, Lille / K. CAMPBELL, Centre Hospitalier Universitaire de Caen, Caen.

Authors contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Julia Mercier, Manon Ruffin, Erika Sutanto, Anthony Kicic, Claire Calmel, Julie Mézinèle, Fathia Merabtene, Elisabeth Longchamp, Edouard Sage. The first draft of the manuscript was written by Julia Mercier and all authors commented on following versions of the manuscript. All authors read and approved the final manuscript.

Running title: SLC6A14 in cystic fibrosis lung pathophysiology

Funding: JM received a doctoral fellowship from the French Ministry of Higher Education, Research and Innovation. MR received a post-doctoral fellowship from the French cystic-fibrosis non-profit organization *Vaincre la mucoviscidose* (RF20180502243, RF20190502451). LG received a grant from the French cystic-fibrosis non-profit organization *Vaincre la mucoviscidose* (RF20170501936, RF20180502243, RF20190502451).

References

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK *et al.* (1989) Identification of the cystic fibrosis gene: genetic analysis. *Science* 245 (4922):1073-1080. doi:10.1126/science.2570460
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R *et al.* (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 245 (4922):1066-1073. doi:10.1126/science.2475911
3. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G *et al.* (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 245 (4922):1059-1065. doi:10.1126/science.2772657
4. Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK *et al.* (2016) Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. *Genetics in medicine : official journal of the American College of Medical Genetics* 18 (4):333-340. doi:10.1038/gim.2015.79
5. Macdonald JA, Trusler GA (1960) Meconium ileus: an eleven-year review at the Hospital for Sick Children, Toronto. *Canadian Medical Association journal* 83 (17):881-885
6. Parikh NS, Ibrahim S, Ahlawat R (2021) Meconium Ileus. In: StatPearls. StatPearls Publishing
Copyright © 2021, StatPearls Publishing LLC., Treasure Island (FL),
7. Elborn JS (2016) Cystic fibrosis. *Lancet* 388 (10059):2519-2531. doi:10.1016/S0140-6736(16)00576-6
8. Cutting GR (2015) Cystic fibrosis genetics: from molecular understanding to clinical application. *Nat Rev Genet* 16 (1):45-56. doi:10.1038/nrg3849
9. Corvol H, Blackman SM, Boelle PY, Gallins PJ, Pace RG *et al.* (2015) Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. *Nat Commun* 6:8382. doi:10.1038/ncomms9382
10. Jain-Vakkalagadda B, Pal D, Gunda S, Nashed Y, Ganapathy V *et al.* (2004) Identification of a Na⁺-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. *Mol Pharm* 1 (5):338-346
11. Palazzolo L, Paravicini C, Laurenzi T, Adobati S, Saporiti S *et al.* (2019) SLC6A14, a Pivotal Actor on Cancer Stage: When Function Meets Structure. *SLAS discovery : advancing life sciences R & D* 24 (9):928-938. doi:10.1177/2472555219867317
12. Sloan JL, Mager S (1999) Cloning and functional expression of a human Na⁽⁺⁾ and Cl⁽⁻⁾-dependent neutral and cationic amino acid transporter B(0+). *J Biol Chem* 274 (34):23740-23745. doi:10.1074/jbc.274.34.23740

13. Ruffin M, Mercier J, Calmel C, Mesinele J, Bigot J *et al.* (2020) Update on SLC6A14 in lung and gastrointestinal physiology and physiopathology: focus on cystic fibrosis. *Cell Mol Life Sci* 77 (17):3311-3323. doi:10.1007/s00018-020-03487-x
14. Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK *et al.* (2016) Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. *Br J Pharmacol* 173 (23):3292-3306. doi:10.1111/bph.13616
15. Sun L, Rommens JM, Corvol H, Li W, Li X *et al.* (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. *Nat Genet* 44 (5):562-569. doi:10.1038/ng.2221
16. Li W, Soave D, Miller MR, Keenan K, Lin F *et al.* (2014) Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. *Hum Genet* 133 (2):151-161. doi:10.1007/s00439-013-1363-7
17. Pereira SV, Ribeiro JD, Bertuzzo CS, Marson FAL (2017) Association of clinical severity of cystic fibrosis with variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1 and SLC9A3). *Gene* 629:117-126. doi:10.1016/j.gene.2017.07.068
18. Sun L, Rommens JM, Corvol H, Li W, Li X *et al.* (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. 44 (5):562-569. doi:10.1038/ng.2221
19. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A *et al.* (2018) ECFS best practice guidelines: the 2018 revision. *J Cyst Fibros* 17 (2):153-178. doi:10.1016/j.jcf.2018.02.006
20. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL *et al.* (2012) Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 40 (6):1324-1343. doi:10.1183/09031936.00080312
21. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL *et al.* (2005) Disease-specific reference equations for lung function in patients with cystic fibrosis. *Am J Respir Crit Care Med* 172 (7):885-891. doi:10.1164/rccm.200410-1335OC
22. Bellec J, Bacchetta M, Losa D, Anegón I, Chanson M *et al.* (2015) CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells. *Curr Gene Ther* 15 (5):447-459
23. Di Paola M, Park AJ, Ahmadi S, Roach EJ, Wu YS *et al.* (2017) SLC6A14 Is a Genetic Modifier of Cystic Fibrosis That Regulates *Pseudomonas aeruginosa* Attachment to Human Bronchial Epithelial Cells. *MBio* 8 (6). doi:10.1128/mBio.02073-17

24. Ruffin M, Bilodeau C, Maillé É, LaFayette SL, McKay GA *et al.* (2016) Quorum-sensing inhibition abrogates the deleterious impact of *Pseudomonas aeruginosa* on airway epithelial repair. *FASEB journal* : official publication of the Federation of American Societies for Experimental Biology 30 (9):3011-3025. doi:10.1096/fj.201500166R
25. Valera FCP, Ruffin M, Adam D, Maillé É, Ibrahim B *et al.* (2019) *Staphylococcus aureus* impairs sinonasal epithelial repair: Effects in patients with chronic rhinosinusitis with nasal polyps and control subjects. *The Journal of allergy and clinical immunology* 143 (2):591-603.e593. doi:10.1016/j.jaci.2018.05.035
26. Karunakaran S, Umapathy NS, Thangaraju M, Hatanaka T, Itagaki S *et al.* (2008) Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. *Biochem J* 414 (3):343-355. doi:10.1042/BJ20080622
27. Sikder MOF, Sivaprakasam S, Brown TP, Thangaraju M, Bhutia YD *et al.* (2020) SLC6A14, a Na⁺/Cl⁻-coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling. *Biochem J* 477 (8):1409-1425. doi:10.1042/BCJ20200099
28. Gong J, Wang F, Xiao B, Panjwani N, Lin F *et al.* (2019) Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. *PLoS Genet* 15 (2):e1008007. doi:10.1371/journal.pgen.1008007
29. Sikder MOF, Yang S, Ganapathy V, Bhutia YD (2017) The Na⁽⁺⁾/Cl⁽⁻⁾-Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB(0,+)): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis. *AAPS J* 20 (1):12. doi:10.1208/s12248-017-0164-7
30. Sivaprakasam S, Sikder MOF, Ramalingam L, Kaur G, Dufour JM *et al.* (2021) SLC6A14 deficiency is linked to obesity, fatty liver, and metabolic syndrome but only under conditions of a high-fat diet. *Biochim Biophys Acta Mol Basis Dis* 1867 (5):166087. doi:10.1016/j.bbadis.2021.166087
31. Ahmadi S, Wu YS, Li M, Ip W, Lloyd-Kuzik A *et al.* (2019) Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis. *American journal of respiratory cell and molecular biology* 61 (6):755-764. doi:10.1165/rcmb.2019-00940C
32. Hibbard HAJ, Reynolds MM (2019) Fluorescent nitric oxide donor for the detection and killing of *Pseudomonas aeruginosa*. *Journal of materials chemistry B* 7 (12):2009-2018. doi:10.1039/c8tb02552e
33. Ahmadi S, Xia S, Wu YS, Di Paola M, Kissoon R *et al.* (2018) SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion. *Elife* 7. doi:10.7554/eLife.37963
34. Ruffin M, Brochiero E (2019) Repair Process Impairment by *Pseudomonas aeruginosa* in Epithelial Tissues: Major Features and Potential Therapeutic Avenues. *Front Cell Infect Microbiol* 9:182.

35. Mao H, Sheng J, Jia J, Wang C, Zhang S *et al.* (2021) Aberrant SLC6A14 Expression Promotes Proliferation and Metastasis of Colorectal Cancer via Enhancing the JAK2/STAT3 Pathway. *Onco Targets Ther* 14:379-392. doi:10.2147/OTT.S288709

36. Liu GY, Sabatini DM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. *Nat Rev Mol Cell Biol* 21 (4):183-203. doi:10.1038/s41580-019-0199-y

37. Kaur H, Moreau R (2019) Role of mTORC1 in intestinal epithelial repair and tumorigenesis. *Cellular and molecular life sciences : CMLS* 76 (13):2525-2546. doi:10.1007/s00018-019-03085-6

38. Raslan AA, Yoon JK (2020) WNT Signaling in Lung Repair and Regeneration. *Molecules and cells* 43 (9):774-783. doi:10.14348/molcells.2020.0059

Tables

Table 1. Demographic and clinical characteristics of 3,257 patients with cystic fibrosis analyzed in the phenotype-genotype study

Characteristics	Patients analyzed in SLC6A14 rs3788766 study
Age at inclusion (years), mean ± SD	21.5 ± 8.4
Females, % (n)	49% (1581)
Caucasian origin, % (n)	91% (2976)
Lung transplant, % (n)	17% (567)
CFTR modulator therapy [#] , % (n)	29% (935)
CFTR genotypes, % (n)	
F508del homozygous	54% (1750)
F508del heterozygous	35% (1154)
Others	11% (353)
[#] Patients who have started CFTR modulator therapy with ivacaftor or lumacaftor-ivacaftor. CFTR: cystic fibrosis transmembrane conductance regulator	

Table 2. Genotype-phenotype association study between lung disease severity and *SLC6A14* rs3788766 genotypes, in 3,257 patients with cystic fibrosis

<i>SLC6A14</i> rs3788766 genotypes	Patients analyzed % (n)	Lung function ppFEV ₁ [#]	Lung disease severity SaKnorm Z-value ^{##}	<i>P</i> -value [†]
		mean ± SD	mean ± SD	
AA	50% (1624)	64.9 ± 27.2	0.360 ± 0.795	0.020
AG	23% (740)	63.5 ± 25.7	0.302 ± 0.797	
GG	27% (893)	63.1 ± 26.4	0.287 ± 0.780	

[#]ppFEV₁: Percent-predicted (pp) Forced expiratory volume in one second (FEV₁). SaKnorm: Survival adjusted Kulich Normalized. [†]*P*-value was computed by linear regression with additive model.

Table 3. Characteristics of the patients from whom the primary bronchial epithelial cells were obtained.

Patient	Age	Sex	Smoker	Pathology	<i>CFTR</i> variant	Figure
CFAB060901	21	Female	No	CF	F508del/F508del	3A, 3B, 3C
CFAB056701	39	Female	No	CF	F508del/F508del	3C
CFAB45202	32	Male	No	CF	F508del/F508del	3B
CFAB064901	37	Female	No	CF	F508del/1717-1G>A	3C
02AB77201F2	63	Male	No	None	-	S3A
02AB067101	72	Male	No	None	-	S3B
02AB068001F2	71	Female	No	None	-	S3B
02AB083901	59	Male	No	None	-	S3B

Figures

FIGURE 1

Figure 1

SLC6A14 rs3788766 variant is associated with gene transcription regulation. A. Graphical representation of the localization of rs3788766 and SLC6A14 gene on X chromosome. B. Violin plots of SLC6A14 transcript expression in tissues according to rs3788766 genotypes in Genotype-Tissue Expression (GTEx, <https://www.gtexportal.org/home/>). C. Representative images of SLC6A14 immunohistochemistry on pwCF lung biopsy. D. SLC6A14 promoter activity measurement was performed on Calu-3-CFTR-KD

transfected with the reporter plasmid constructs containing A allele or G allele of rs3788766 (n=8) (Wilcoxon test, **p<0.01).

FIGURE 2

Figure 2

Effect of SLC6A14 inhibition in Calu-3-CFTR-KD cells. A. 3H-Arginine uptake in Calu-3-CFTR-KD cells treated with α-MT (2.5mM) or vehicle (MeOH) (n=9, Wilcoxon test, *p<0.05). B. Calu-3-CFTR-KD were treated with increasing doses of α-MT or vehicle (MeOH) for 6 h. Quantification of wound closure

expressed in mean % compared to the control condition (n=6, ANOVA followed by Bonferroni's multiple comparison test, * p<0.05, ** p<0.01). C. Representative images of wounds at 0h and 6h in control (MeOH) and α-MT conditions. Wounds have been brightened on the pictures and white lines have been drawn at the wound edges for a better visualization.

FIGURE 3

Figure 3

Effect of SLC6A14 inhibition in CF primary human bronchial epithelial cells (HBEC). A. 3H-arginine uptake in CF primary HBEC treated or not with α -MT (n=3, ANOVA followed by Bonferroni's multiple comparison test, * p<0.05, ** p<0.01). B. Measurement of epithelial repair (6 h) of CF primary HBEC treated with increasing doses of α -MT or vehicle (MeOH). Quantification of wound closure is expressed in mean % compared to the control condition (n=4, ANOVA followed by Bonferroni's multiple comparison test, * p<0.05). C. Western blot, images of phospho-mTOR, total mTOR and β -actin (loading control) (left) and quantification of P-mTOR / mTOR ratio (right) in CF primary HBEC treated 6 h with 2.5 mM α -MT or control vehicle (MeOH). Test * p<0.05.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS1.tif](#)
- [FigureS2.tif](#)
- [FigureS3.tif](#)